Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.My back ground story is here:

Tuesday, May 15, 2018

Nanoparticle Atherosclerosis Tx Promising in Early Study

Did your doctors know about this study before you told them?

Injecting targeted nanofibers reduced atherosclerotic plaques

  • by Contributing Writer, MedPage Today
  • This article is a collaboration between MedPage Today® and:
    Medpage Today
A novel nanofiber approach targeting atherosclerosis may rapidly reduce plaque burden, a mouse study suggested.
At 8 weeks of treatment with the nanofiber incorporating a liver X receptor agonist, plaques were 11% and 9% smaller by area in male and female mice, respectively, reported Neel Mansukhani, MD, of Northwestern University in Chicago, in a poster at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions in San Francisco.
Mansukhani and colleagues said this shows that their novel approach is specific to atherosclerotic lesions and reduces plaque burden after a short time.
"This therapy is designed to be injected systemically but to target and exert its effects only at areas of atherosclerosis. This allows for lower effective doses of therapeutic agents which may otherwise be toxic at higher doses required for efficacy with systemic administration," he told MedPage Today.
The researchers fed these LDL receptor-knockout mice a high-fat diet for 14 weeks and subsequently gave the animals biweekly injections of self-assembling peptide amphiphile nanofibers or control for 8 weeks. At an optimum concentration of 2 mg/mL, the nanofiber could be targeted to atherosclerotic plaque in the aortic root, localizing there for 2 to 3 days before clearing out during days 7 to 10.
Nicholas Leeper, MD, of Stanford University, California, also said that the specificity of these nanoparticles made the study "very exciting."
"The field of nanotherapies has recently expanded beyond its origins as a platform for cancer theranostics into the cardiovascular realm. Work in this area promises to allow precision treatment of atherosclerosis, which remains the leading cause of death in the United States," commented Leeper, who was not part of the study.
Nanofiber therapy for atherosclerosis still needs further study in animal models before moving onto humans, Mansukhani cautioned, adding that next steps include accurately classifying how the liver X receptor agonist is released from the nanofiber and investigating other potential therapeutic agents.
The study was funded by grants from the National Heart, Lung, and Blood Institute of the NIH and the American Medical Association Foundation.
Mansukhani and Leeper disclosed no relevant conflicts of interest.

No comments:

Post a Comment